Results 151 to 160 of about 357,544 (339)

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

Advanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason, Anindya Sen, Suhan Cho, Se Jong Lee, Keyata Thompson, Md Musavvir Mahmud, Poornima Dubey, Talia Guardia, Anthony Kim, Stuart Martin, Nathan Wright, Konstantinos Konstantopoulos, Aikaterini Kontrogianni‐Konstantopoulos   +12 more
wiley   +1 more source

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients

Bangladesh Journal of Pharmacology, 2015
We investigated dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment on stage II-IV ovarian cancer patients.
Zhenhua Du, Xiaolin Ma
doaj  

Cyclosporine A Decreased Paclitaxel Resistance in Prostate Cancer Cells by Inhibiting MTDH Expression

American Journal of Men's Health
This study aims to investigate the effect and mechanism of cyclosporine A (CsA) on paclitaxel-resistant prostate cancer cells. Paclitaxel-resistant prostate cancer cell lines were established by gradual increment method.
Jiangtao Li, Yuzhi Li, Xiaohong Zhang, Kun Liu, Shiping Yang, Zhang Liu, Sheng Cao, Dongfei Ren, Menghui Cui, Jia Su, Zewang Zhen, Donghong Zhang   +11 more
doaj   +1 more source

Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]

, 2013
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R, Guru Prasad B, B, Kundargi, R, Lakshmaia, KC, Purohit, S, Shetty, R   +5 more
core   +1 more source

Paclitaxel: What has been done and the challenges remain ahead.

International journal of pharmaceutics, 2017
In recent years, the nanotechnology has offered researchers the opportunity to solve the problems caused by the vehicle of the standard and first formulation of paclitaxel (Taxol®), while maximizing the proven antineoplastic activity of the drug against ...
E. Bernabeu, Maximiliano Cagel, E. Lagomarsino, M. Moretton, D. Chiappetta   +4 more
semanticscholar   +1 more source

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

A Dual‐Responsive Versatile Nanohybrid Orchestrating Tumor Elimination and Tumor‐Associated Osteolysis Restoration via Sequential Release

Advanced Science, EarlyView.
The versatile CaO2@CuMOF@HAP nanohybrid demonstrates an outstanding MMP9/pH‐triggered release performance for sequential release of osteogenic growth peptide into deep‐seated tumor‐infiltrated bone destruction areas and dual ions into tumor cells, enabling efficient tumor‐associated osteolysis restoration and tumor elimination for more comprehensive ...
Lan Liu, Han‐Zhe Liu, Zhe‐Nan Liu, Tong Wang, Li‐Li Yu, Qiu‐Jing Li, Zi‐Yi Chen, Guo‐Feng Luo, Zheng‐Jun Shang   +8 more
wiley   +1 more source

RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer

Clinical and Translational Medicine
Background Resistance to paclitaxel‐based chemotherapy is the major obstacle in triple‐negative breast cancer (TNBC) treatment. However, overcoming paclitaxel resistance remains an unsolved problem. The present study aimed to determine whether paclitaxel
Shumei Huang, Dongni Shi, Shuqin Dai, Xingyu Jiang, Rui Wang, Muwen Yang, Boyu Chen, Xuwei Chen, Lingzhi Kong, Lixin He, Pinwei Deng, Xiangfu Chen, Chuyong Lin, Yue Li, Jun Li, Libing Song, Yawei Shi, Weidong Wei   +17 more
doaj   +1 more source

Tetrastigma Hemsleyanum Polysaccharide Suppresses Triple‐Negative Breast Cancer by Disrupting the Hippo‐YAP/TEAD4‐PDIA4 Axis and Endoplasmic Reticulum Stress Adaptation

Advanced Science, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) exhibits addiction to chronic endoplasmic reticulum (ER) stress, which sustains an aggressive metastatic phenotype through activation of the unfolded protein response (UPR). Here, we identify a previously unrecognized “ER‐stress addiction” axis in which the Hippo pathway effector TEAD4 directly ...
Yini Shang, Wentao Si, Youxue Zhang, Jialin Liu, Huaixi Zhang, Yafei Li, Hongmeng Su, Wei Jiang, Zhishan Ding, Lihong Wang   +9 more
wiley   +1 more source